Loading company…
Renalys Pharma develops treatments for kidney diseases, including chronic and end-stage renal disease.
Founded in 2024, Renalys Pharma develops medicines for renal disease patients in Japan and other Asian countries. Its pipeline includes sparsentan, an oral dual endothelin angiotensin receptor antagonist for IgA nephropathy. The company is based in Chuo-ku, Japan, and was founded by CEO BT Slingsby and CFO Takeshi Takahashi. Catalys Pacific and SR One formed the company in January 2024.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in